22.09.2022 • NewsBachemPeptidesOligonucleotides

Bachem Secures Major Peptide Contracts

Bachem, a Swiss specialist developer and manufacturer of peptides and oligonucleotides, has announced the signing of two major contracts for supplying large volumes of peptides over the next two years. The orders are worth 25 million and 150 million Swiss francs for 2023 and 2024, respectively.

The name of the customer was not disclosed, but Bachem said the parties are currently negotiating for further “significantly” higher orders for the following years.

“The need for peptide manufacturing and development capabilities across the biopharma industry is growing at a fast pace. That is why we are rapidly and consistently expanding our manufacturing base,” said CEO Thomas Meier.

Bachem is currently implementing an investment program across all its sites to expand capacity. One of the projects is the addition of a new large-scale facility in Bubendorf, Switzerland. Construction started last November and the plant is scheduled to open in 2024.

The project is being undertaken in two phases. The first will see an investment of 220 million Swiss francs, with a second sum of 150 million Swiss francs for phase two. In its final form, the facility will more than double capacity at Bubendorf.

Foto: Bachem
Foto: Bachem

In addition, Bachem is in the advanced stages of selecting a location for a third site in Switzerland as the company aims to strengthen its production network by the end of the decade. It said land reserves at the Bubendorf site will be exhausted in the medium term. Capacity expansions are also underway in Vionnaz, Switzerland; Torrance and Vista in California, USA; and St. Helens in the UK.

In April this year, Bachem announced it had entered into a strategic collaboration with major drugmaker Eli Lilly to develop and manufacture APIs based on oligonucleotides. Under the terms of the agreement, Bachem is supplying appropriate engineering infrastructure and expertise to implement Lilly’s novel manufacturing technology.

Furthermore, Bachem is providing R&D and production personnel at its Bubendorf site to develop and manufacture GMP-grade material for Lilly’s oligonucleotide-based investigational medicines.

For its part, Lilly committed to place manufacturing projects with Bachem over the next seven years, with increasing demands for material following the successful implementation of its technology. Annual order volumes could potentially reach about 100 million Swiss francs, depending on Bachem achieving certain milestones and definite volumes ordered by Lilly.

Author: Elaine Burridge, Freelance Journalist

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.